The effect of apremilast therapy on skin cytokine levels in patients with psoriasis

• DOI: 10.15275/rusomj.2020.0310
• Publication Date: 2020-10-01T15:59:04Z
• Authors: Alexey A. Kubanov; Viktoria S. Solomka; Arfenya E. Karamova; Dmitry A. Verbenko; Elena L. Vasileva; Olga G. Artamonova
• Keywords: Apremilast

Objective — Assessment of phosphodiesterase-4 inhibitor (apremilast) therapy’s influence on skin cytokine levels in patients with moderate-to-severe and severe psoriasis. Material Methods An open, uncontrolled study was conducted. 16 plaque psoriasis (13 men, 3 women; mean ± standard deviation (SD) age 35.1±9.7 years, range 21-60) were enrolled. The Psoriasis Area Severity Index (PASI) 20.7±8.93 (range 10-47). All prescribed apremilast 30 milligrams (mg) per os (PO) Bis In Die (BID). efficacy therapy evaluated by PASI at 14 26 weeks therapy. Lesional samples collected baseline 26. Levels interleukin (IL)-1β, IL-4, IL-6, IL-10, IL-17A, IL-17F, IL-21, IL-22, IL-23, IL-25, IL-31, IL -33, interferon (INF)-γ, Soluble CD40-ligand (sCD40L), tumor necrosis factor (TNF)-α measured microsphere-based suspension array technology (Luminex® xMAP™ system). Results cytokines (except IL-4 IL-33) lesional found to have decreased week compared those baseline. Similar decreases seen for sCD40L contrast, the other increased again 26, comparison IL-33 rose throughout follow-up period. Cytokine healthy controls both during Conclusion results our show that administering can bring involved IL-23/IL-17 axis level non-lesional individuals.